Takeda launches hemophilia drug Adynovate in India
Takeda Pharma has expanded its unique rare diseases portfolio in India with the launch of Adynovate, an extended half-life recombinant Factor VIII (rFVIII) medication for haemophilia A patients that uses existing technology (controlled PEGylation). It also stated that Adynovate, when used in conjunction with MYPKFIT, the first and only FDA-approved app, provides a personalised and …
Takeda launches hemophilia drug Adynovate in India Read More »